AstraZeneca has announced the US launch of its Airsupra albuterol / budesonide MDI, which was approved by the FDA in January 2023 for the treatment of asthma in people aged 18 and over. Airsupra (PT027) was developed by AstraZeneca subsidiary Pearl Therapeutics. The company points out that the MDI is the only approved SABA/ICS inhaler and the only one that includes both a medication for prevention of symptoms and a rescue medication.
AstraZeneca VP, US Respiratory & Immunology, Liz Bodin commented, “With Airsupra now available in the US, we are taking an important step in our mission to revolutionize asthma for millions of people living with the disease. We are hopeful our innovative asthma rescue medicine can help alleviate the burden by addressing both symptoms and underlying inflammation simultaneously at the right time to reduce the risk of having a severe asthma attack.”
Read the AstraZeneca press release.
